The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
Open accessAbstract
BACKGROUND: Restenosis after coronary stenting necessitates repeated percutaneous or surgical revascularization procedures. The delivery of paclitaxel to the site of vascular injury may reduce the incidence of neointimal hyperplasia and restenosis. METHODS: At 73 U.S. centers, we enrolled 1314 patients who were receiving a stent in a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm) in a prospective, randomized, double-blind study. A total of 652 patients were randomly assigned to receive a bare-metal stent, and 662 to receive an identical-appearing, slow-release, polymer-based, paclitaxel-eluting stent. Angiographic follow-up was prespecified at nine months in 732 patients. RESULTS: In terms of base-line characteristics, the two groups were well matched. Diabetes mellitus was present in 24.2 percent of patients; the mean reference-vessel diameter was 2.75 mm, and the mean lesion length was 13.4 mm. A mean of 1.08 stents (length, 21.8 mm) were implanted per patient. The rate of ischemia-driven target-vessel revascularization at nine months was reduced from 12.0 percent with the implantation of a bare-metal stent to 4.7 percent with the implantation of a paclitaxel-eluting stent (relative risk, 0.39; 95 percent confidence interval, 0.26 to 0.59; P<0.001). Target-lesion revascularization was required in 3.0 percent of the group that received a paclitaxel-eluting stent, as compared with 11.3 percent of the group that received a bare-metal stent (relative risk, 0.27; 95 percent confidence interval, 0.16 to 0.43; P<0.001). The rate of angiographic restenosis was reduced from 26.6 percent to 7.9 percent with the paclitaxel-eluting stent (relative risk, 0.30; 95 percent confidence interval, 0.19 to 0.46; P<0.001). The nine-month composite rates of death from cardiac causes or myocardial infarction (4.7 percent and 4.3 percent, respectively) and stent thrombosis (0.6 percent and 0.8 percent, respectively) were similar in the group that received a paclitaxel-eluting stent and the group that received a bare-metal stent. CONCLUSIONS: As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serruys, P. W., de Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, G., Emanuelsson, H., Marco, J., Legrand, V., Materne, P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310801 · Cited by 4,556
Fischman, D. L., Leon, M. B., Baim, D. S., Schatz, R. A., Savage, M. P., Penn, I., Detre, K., Veltri, L., Ricci, D., Nobuyoshi, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310802 · Cited by 4,271
Self-citationMoses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
Self-citationMorice, M.-C., Serruys, P. W., Sousa, J. E., Fajadet, J., Ban Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012843 · Cited by 4,033
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Angiographic Patterns of In-Stent Restenosis: Classification and Implications for Long-Term Outcome
Mehran, R., Dangas, G., Abizaid, A. S., Mintz, G. S., Lansky, A. J., Satler, L. F., Pichard, A. D., Kent, K. M., Stone, G. W., & Leon, M. B. (1999) · Circulation · doi:10.1161/01.cir.100.18.1872 · Cited by 1,258
Self-citationColombo, A., Drzewiecki, J., Banning, A., Grube, E., Hauptmann, K., Silber, S., Dudek, D., Fort, S., Schiele, F., Zmudka, K., et al. (2003) · Circulation · doi:10.1161/01.cir.0000086926.62288.a6 · Cited by 1,016
Self-citationPathology of Acute and Chronic Coronary Stenting in Humans
Farb, A., Sangiorgi, G., Carter, A. J., Walley, V. M., Edwards, W. D., Schwartz, R. S., & Virmani, R. (1999) · Circulation · doi:10.1161/01.cir.99.1.44 · Cited by 871
Grube, E., Silber, S., Hauptmann, K. E., Mueller, R., Buellesfeld, L., Gerckens, U., & Russell, M. E. (2003) · Circulation · doi:10.1161/01.cir.0000047700.58683.a1 · Cited by 865
Self-citationAxel, D. I., Kunert, W., Göggelmann, C., Oberhoff, M., Herdeg, C., Küttner, A., Wild, D. H., Brehm, B. R., Riessen, R., Köveker, G., et al. (1997) · Circulation · doi:10.1161/01.cir.96.2.636 · Cited by 784
Predictive Factors of Restenosis After Coronary Stent Placement
Kastrati, A., Schömig, A., Elezi, S., Schühlen, H., Dirschinger, J., Hadamitzky, M., Wehinger, A., Hausleiter, J., Walter, H., & Neumann, F.-J. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00334-3 · Cited by 685
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., & Taraboletti, G. (1996) · PubMed · Cited by 643
Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent
Farb, A., Heller, P. F., Shroff, S., Cheng, L., Kolodgie, F. D., Carter, A. J., Scott, D. S., Froehlich, J., & Virmani, R. (2001) · Circulation · doi:10.1161/hc3001.092037 · Cited by 423
Wang, T.-H., Wang, H.-S., Ichijo, H., Giannakakou, P., Foster, J. S., Fojo, T., & Wimalasena, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.4928 · Cited by 353
Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo
Herdeg, C., Oberhoff, M., Baumbach, A., Blattner, A., Axel, D. I., Schröder, S., Heinle, H., & Karsch, K. R. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00614-8 · Cited by 276
Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.
Sollott, S. J., Cheng, L., Pauly, R. R., Jenkins, G. M., Monticone, R. E., Kuzuya, M., Froehlich, J. P., Crow, M. T., Lakatta, E. G., & Rowinsky, E. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117867 · Cited by 253
Coronary in-stent restenosis—predictors, treatment and prevention
Hoffmann, R. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2153 · Cited by 233
Giannakakou, P., Robey, R., Fojo, T., & Blagosklonny, M. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204487 · Cited by 229
Al Suwaidi, J. (2000) · JAMA · doi:10.1001/jama.284.14.1828 · Cited by 211
van der Zwet, P. M. J., & Reiber, J. H. C. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90566-5 · Cited by 197
Clinical and quantitative coronary angiographic predictors of coronary restenosis
Mercado, N., Boersma, E., Wijns, W., Gersh, B. J., Morillo, C. A., de Valk, V., van Es, G.-A., Grobbee, D. E., & Serruys, P. W. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01431-0 · Cited by 175
Serruys, P. W., Kay, I. P., Disco, C., Deshpande, N. V., & de Feyter, P. J. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00308-3 · Cited by 170
Mitsuuchi, Y., Johnson, S. W., Selvakumaran, M., Williams, S. J., Hamilton, T. C., & Testa, J. R. (2000) · PubMed · Cited by 137
Signore, P. E., Machan, L. S., Jackson, J. K., Burt, H. M., Bromley, P., Wilson, J. E., & McManus, B. M. (2001) · Journal of Vascular and Interventional Radiology · doi:10.1016/s1051-0443(07)61408-0 · Cited by 56
Hui, A., Min, W., Tang, J., & Cruz, T. F. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199805)41:5<869::aid-art15>3.0.co;2-3 · Cited by 52
Effects of taxol on human neutrophils.
Roberts, R. L., Nath, J., Friedman, M. M., & Gallin, J. I. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.5.2134 · Cited by 44
Jackson, J. K., Tudan, C., Bill, S. A. H. L., Pelech, S., & Burt, H. M. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.d01-2178.x · Cited by 31
Cited by
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), Authors/Task Force Members, Wijns, W., Kolh, P., Danchin, N., Di Mario, C., Falk, V., Folliguet, T., Garg, S., Huber, K., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq277 · Cited by 3,184
Iakovou, I. (2005) · JAMA · doi:10.1001/jama.293.17.2126 · Cited by 3,132
Pathology of Drug-Eluting Stents in Humans
Joner, M., Finn, A. V., Farb, A., Mont, E. K., Kolodgie, F. D., Ladich, E., Kutys, R., Skorija, K., Gold, H. K., & Virmani, R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.042 · Cited by 2,744
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Metadata
- Authors
- Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O'Shaughnessy, C., Mann, J. T., Turco, M., Caputo, R., Bergin, P., Greenberg, J., Popma, J. J., & Russell, M. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-15
- Volume
- 350
- Issue
- 3
- Pages
- 221-231
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989556574
- Cited by
- 2,749
- References
- 27
- FWCI
- 271.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.